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KESAN PERLINDUNGAN NEFRO DAUN-DAUN CLINACANTHUS 
NUTANS, ORTHOSIPHON STAMINEUS, DAN SYZYGIUM 
CAMPANULATUM TERHADAP KENEFROTOKSIKAN TERARUH-
CISPLATIN DAN PENILAIAN KESELAMATAN DAUN CLINACANTHUS 
NUTANS 
ABSTRAK 
Cisplatin adalah ejen kemoterapi berkesan untuk tumor pepejal. Walau 
bagaimanapun, ia juga mendorong kenefrotoksikan yang tidak boleh diubah dan 
progresif bergantung kepada dos. Cisplatin mempunyai pelbagai kesan intrasel, 
termasuk menyebabkan kesitotoksikan langsung dengan spesies oksigen reaktif, 
mengaktifkan apoptosis, dan merangsang keradangan, yakni peristiwa-peristiwa yang 
menyebabkan disfungsi tiub dan vaskular. Model haiwan telah menunjukkan bahawa 
ketoksikan buah pinggang teraruh cisplatin dicirikan oleh kehilangan pesat penapisan 
glomerular, polyuria, hyperkalemia, hypernatremia dan azotemia. Baru-baru ini, 
banyak perhatian telah diberikan kepada peranan kemungkinan perubatan herba dalam 
melindungi ketoksikan buah pinggang teraruh cisplatin. Banyak produk herba yang 
kaya dengan fitokimia bersama dengan aktiviti anti-apoptotik, antioksidan, dan anti-
radang. Faktor-faktor ini mungkin berguna dalam melindungi buah pinggang daripada 
kerosakan teraruh cisplatin dan, digabungkan dengan ciri-ciri proangiogenic mereka, 
membantu mempercepatkan proses penyembuhan. Clinacanthus nutans, Orthosiphon 
stamineus dan Syzygium campanulatum adalah herba tropika yang kaya dengan 
antioksidan yang telah digunakan secara tradisional untuk merawat penyakit buah 
pinggang. Kajian ini menyiasat kesan perlindungan ekstrak akueus daun Clinacanthus 
nutans (AECNL), ekstrak hydroethanolic daun Orthosiphon stamineus (HEOSL), dan 
ekstrak daun Syzygium campanulatum (HESCL) terhadap model ketoksikan in vitro 
 xxi 
 
dan in vivo. Aktiviti perlindungan daun-daun tersebut pada sel tiub renal (NRK52-E) 
telah dinilai dari segi kebolehidupan selular (MTT assay) dan apoptosis (Hoechst dan 
Rhodamine 123 mengotorkan), dengan AECNL, HEOSL dan HESCL bersendirian 
atau dalam gabungan dengan cisplatin. Potensi membendung dinilai melalui gavaj oral 
pada haiwan dengan AECNL, HEOSL dan HESCL pada dos 100, 200 atau 400 mg / 
kg selama 90 hari, semasa menerima dos mingguan cisplatin (1 mg / kg). Aktiviti 
biologi AECNL terhadap angiogenesis dinilai menggunakan ex vivo cerakin gelang 
aorta tikus dengan mengukur tahap pertumbuhan vessel mikro daripada gelang 
tersebut. Aktiviti mutagen AECNL (500 μg /well) telah dinilai melalui ujian Ames, 
yang telah dilakukan ke atas Salmonella jenis TA98 dan TA100. Akut, dan kesan 
ketoksikan oral dos berulang 28- dan 90 hari AECNL juga dinilai. Untuk kajian 
ketoksikan akut, dos tunggal 5000 mg / kg AECNL diberikan bagi 28 dan 90 hari 
kajian, manakala 500, 1000, dan 2000 mg / kg / hari telah diberikan kepada kedua-dua 
jantina tikus Sprague-Dawley. Keputusan menunjukkan bahawa cisplatin menurunkan 
kebolehidupan sel, yang dikaitkan dengan peningkatan dalam kesitotoksikan dan 
apoptosis.  Rawatan serentak dengan cisplatin dan AECNL, HEOSL atau HESCL, 
meningkatkan kebolehidupan dan kemandirian sel dan menurunkan kadar apoptosis 
dalam susunan menurun. Kemerosoton penting ketoksikan buah pinggang telah 
disahkan melalui penurunan tahap kreatinin serum dan protein, nitrogen urea darah, 
elektrolit air kencing, dan jumlah air kencing. Tambahan pula, daripada peningkatan 
kadar glomerular penapisan, elektrolit serum, dan air kencing kreatinin, kedua AECNL 
dan HEOSL menunjukkan potensi yang tinggi dan berkesan.  Pengaruh AECNL pada 
angiogenesis adalah jauh (EC50: 47,37) positif, dan keputusan mendedahkan bahawa 
AECNL tidak mutagen dalam auxotrophs S. typhimurium. Dalam kajian ketoksikan 
akut, 28, dan 90 hari, tidak ada morbiditi atau kematian diperhatikan, dengan nilai-
 xxii 
 
nilai LD50 atas 5000 mg / kg. Walaupun perubahan ketara diperhatikan dalam 
hematologi dan parameter biokimia, pemeriksaan histopatologi dan berat relatif organ-
organ utama tidak menunjukkan apa-apa tanda-tanda ketoksikan yang ketara. 
Berdasarkan penemuan ini, NOAEL daripada kajian dos oral berulang 28- dan 90-hari 
disimpulkan berada di bawah 2000 mg / kg untuk kedua-dua tikus jantan dan betina. 
Secara kolektif, data ini menyerlahkan potensi penggunaan AECNL dalam pengurusan 
dan rawatan kenefrotoksikan teraruh cisplatin melalui peningkatan kebolehidupan sel, 
penurunan apoptosis, angiogenesis, dan pengawalseliaan parameter klinikal serum dan 
air kencing. Keupayaan AECNL untuk mengurangkan kesan kemoterapi daripada 
cisplatin, bagaimanapun, mencegah pemberian serentak kepada pesakit-pesakit 
kanser. Tambahan pula, walaupun kajian ini menunjukkan tingkah laku yang bukan 
toksik AECNL pada tikus, langkah berhati-hati perlu dilaksanakan dalam aplikasi 
klinikal, terutama di kalangan pesakit yang mengalami masalah perubatan lain..  
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NEPHROPROTECTIVE EFFECT OF CLINACANTHUS NUTANS, 
ORTHOSIPHON STAMINEUS, AND SYZYGIUM CAMPANULATUM 
LEAVES AGAINST CISPLATIN-INDUCED NEPHROTOXICITY; AND 
SAFETY ASSESSMENT OF CLINACANTHUS NUTANS LEAVES. 
ABSTRACT 
Cisplatin is an effective chemotherapeutic agent for solid tumors. However, it 
also induces dose-dependent progressive and irreversible nephrotoxicity. Cisplatin has 
multiple intracellular effects, which includes causing direct cytotoxicity with reactive 
oxygen species, activating apoptosis, and stimulating inflammation, events of which 
cause vascular and tubular dysfunction. Animal models have demonstrated that 
cisplatin-induced renal toxicity is characterized by a rapid loss of glomerular filtration, 
polyuria, hyperkalemia, hypernatremia, and azotemia. Recently, much attention has 
been given to the possible role of herbal medicine in protecting against cisplatin-
induced renal toxicity. Many herbal products are rich in phytochemicals with 
antiapoptotic, antioxidant, and anti-inflammatory activity. These factors may be useful 
in protecting kidneys from cisplatin-induced damage and, combined with their 
proangiogenic properties, help expedite the healing process. Clinacanthus nutans, 
Orthosiphon stamineus, and Syzygium campanulatum are antioxidant-rich tropical 
herbs that have been traditionally used to treat kidney diseases. This study investigates 
the protective effects of the aqueous extract of Clinacanthus nutans leaves (AECNL), 
the hydroethanolic extract of Orthosiphon stamineus leaves (HEOSL), and the extract 
of Syzygium campanulatum leaves (HESCL) on in vitro and in vivo toxicity models. 
Their protective activities on renal tubular cell (NRK52-E) were evaluated in terms of 
cellular viability (MTT assay) and apoptosis (Hoechst and Rhodamine 123 staining), 
with AECNL, HEOSL, and HESCL alone or in combination, with cisplatin. Their 
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ameliorating potential was evaluated via oral gavage on the animals with AECNL, 
HEOSL, and HESCL at doses of 100, 200 or 400 mg/kg for 90 days, while receiving 
weekly doses of cisplatin (1 mg/kg). The biological activity of AECNL on 
angiogenesis was evaluated using the ex vivo rat aortic ring assay by quantifying the 
degree of microvessel outgrowth from the rings. The mutagenic activity of AECNL 
(500 µg/well) was evaluated by Ames test, which was performed on Salmonella TA98 
and TA100 strains. The acute, and the 28- and 90-day repeated dose oral toxicity effect 
of AECNL was also evaluated. For the acute toxicity study, a single dose of 5000 
mg/kg of AECNL was administered for the 28 and 90-day studies, while 500, 1000, 
and 2000 mg/kg/day was administered to Sprague-Dawley rats of both sex. The results 
demonstrated that cisplatin decreased cell viability, which was associated with an 
increase in cytotoxicity and apoptosis. Simultaneous treatment with cisplatin and 
AECNL, HEOSL, or HESCL enhanced cell survival and viability, and decreased the 
apoptosis rate in a descending order. Significant attenuation of renal toxicity was 
confirmed by decreased levels of serum creatinine and proteins, blood urea nitrogen, 
urine electrolytes, and urine volume. Furthermore, from the increased glomerular 
filtration rate, serum electrolytes, and urine creatinine, both AECNL and HEOSL 
showed high potency and efficacy. The influence of AECNL on angiogenesis was 
significantly (EC50: 47.37) positive, and the results revealed that AECNL was not 
mutagenic in the auxotrophs of S. Typhimurium. In the acute, 28, and 90-day toxicity 
studies, neither morbidity nor mortality was observed, with LD50 values above 5000 
mg/kg. While significant alteration was observed in hematological and biochemical 
parameters, the histopathological examination and the relative weight of the main 
organs did not show any significant toxicity symptoms. Based on these findings, the 
NOAEL of the 28- and 90-day repeated oral dose studies is concluded to be below 
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2000 mg/kg for both male and female rats. Collectively, these data highlight the 
potential use of AECNL in the management and treatment of cisplatin-induced 
nephrotoxicity through increased cell viability, decreased apoptosis, angiogenesis, and 
regulation of serum and urine clinical parameters. The ability of AECNL to decrease 
the chemotherapeutic effect of cisplatin, however, prohibits concurrent administration 
in cancer patients. Furthermore, even though these studies demonstrated the nontoxic 
behavior of AECNL in rats, caution should be exercised in clinical applications, 
especially in patients with other medical conditions. 
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 CHAPTER ONE: INTRODUCTION AND LITERATURE REVIEW 
 Kidneys: Structure and function 
Kidneys are paired, bean-shaped retroperitoneal organs located under the cover of the 
costal margin on either side of the vertebral column. A kidney is about 11 cm long, 6 cm 
wide, 3 cm thick, and weighs approximately 115–170 g. Macroscopically, kidneys are 
characterized by an inner fibrous medulla and outer granular cortex encompassed by a 
capsule of collagenous fibers. Microscopically, they consist of nephrons (functioning 
units of the kidney), blood vessels, lymphatics, and nerves. The cortex contains corpuscles 
(a glomerulus and a Bowman's capsule) and convoluted tubules. The medulla is composed 
of ascending and descending loops of Henle and collecting ducts (Figure 1.1) (Koeppen 
and Stanton, 2013). 
Kidneys are the key organs of the urinary system and have numerous functions such as 
blood filtration, disposal of metabolic waste and exogenous chemicals, regulation of 
electrolytes, acid-base homeostasis, and regulation of blood pressure. Kidneys also have 
endocrine and metabolic functions. However, the pivotal function of the kidneys is 
excretion of exogenous or endogenous toxins. The kidneys use three general mechanisms 
to accomplish this goal: glomerular filtration, tubular reabsorption, and tubular secretion. 
Glomerular filtration is a process by which blood passes through the glomerulus and 
filtrates enter the Bowman's capsule. The filtrates move through the cortical and medullary 
loop of Henle where tubular reabsorption and secretion occurs. Finally, the filtrates and 
water enter collecting ducts to form urine (Daugirdas, 2012). 
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Figure 1.1. Gross anatomic features of the human kidney, the internal structures. A: The 
medial side of each kidney contains an indentation, through which pass the renal artery 
and vein, nerves, and pelvis. B Diagram of a nephron (Koeppen and Stanton, 2013).  
 
 
 
 
 3 
 
 Renal disease and diagnosis 
Renal disease refers to any damage that disrupts the kidneys’ normal glomerular filtration 
process. The renal disease, may be acute or chronic. Acute renal injury (AKI) is ascribed 
to an abrupt or a rapid decline in renal function and often causes severe damage to the 
kidney (Ozkok and Edelstein, 2014). The pathogenesis of AKI is very complicated and 
multifactorial (Table 1.1). However, the major causes of AKI among ambulatory or 
hospitalized patients are ischemia, toxins, or sepsis, alone or in combination (Chawla et 
al., 2014). Twenty percent of all AKI cases are triggered by drug-induced renal injury. 
AKI can lead to chronic kidney disease and end-stage renal failure (ESRF) (Naughton, 
2008). Chronic kidney disease (CKD) is a category of progressive renal disorder that 
occurs complementary to other chronic medical conditions (Table 1.2). Kidney damage 
that lasts for three months or more, regardless of the etiology, is also considered CKD 
(NFK, 2016). CKDs are classified based on the causes of disease, glomerular filtration 
rate stages, and albuminuria stages. CKDs eventually lead to ESRF. The rate of 
developing ESRF, however, varies between patients and depends on the underlying cause. 
ESRF is a permanent kidney failure that necessitates the patient’s dependence on life-long 
dialysis or renal transplant. It is estimated that two million of world’s population suffer 
from ESRF (Levey and Coresh, 2012). Even though there have been significant 
improvements in medical treatment and patient management, the number ESRF cases 
increases annually by 6–8%. It is becoming a huge social and economic burden that needs 
to be addressed (NFK, 2016, Eknoyan et al., 2004). 
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Table 1.1. Common causes of acute kidney disease 
(Ozkok and Edelstein, 2014) 
Table 1.2. Common causes of chronic kidney disease  
Chronic Kidney Disease   
Diabetes 
Hypertension 
Acute kidney injury 
(Levey and Coresh, 2012)  
Intrinsic renal disease Interstitial nephritis Hereditary renal disease 
Acute tubular necrosis  Drug induced Autosomal dominate polycystic kidney disease 
Drug induced Idiopathic Autosomal recessive polycystic kidney disease 
Toxin mediated Glomerulonephritis Alport’s syndrome 
Hypoxic/ischemic insults Vascular lesions Sickle cell nephropathy 
Endogenous toxins - hemoglobin, myoglobin Renal artery thrombosis Juvenile nephronophthisis 
Exogenous toxins - ethylene glycol, methanol Renal vein thrombosis Obstructive uropathy/lower tract lesions 
Uric acid nephropathy and tumor lysis 
syndrome 
Cortical necrosis Obstruction in a solitary kidney 
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 Medication-induced nephrotoxicity  
Kidneys are the recipients of 20 % of the resting cardiac output, which supports 
glomerular filtration and sustains renal metabolism (Guyton and Hall, 2006). High blood 
flow results in greater exposure to a wide range of drugs or their metabolites. Reabsorption 
of water along the nephron concentrates the drug in the lumen and tubular cells. The drug 
accumulates within the proximal tubule cells, which exposes the cells to higher 
concentrations of toxicants than normally occurs in circulation and leads to nephrotoxicity 
(Naughton, 2008). Drug-induced nephrotoxicity is a common complication. It involves 
many classes of prescribed or over-the-counter medicines such as anticancer, antibiotic 
and viral infection, antihypertensive, and antidiabetic (Table 1.3). 
The mechanism of drug-induced nephrotoxicity may vary between different classes of 
medicines. However, most of the drug follows one or a combination of these pathogenic 
mechanisms such as crystal nephropathy, interstitial nephritis, vascular obliteration, 
glomerulonephritis, and tubular cell toxicity. Drug-induced nephrotoxicity is manifested 
by a decline in the glomerular filtration rate, azotemia, electrolyte imbalances, acid-base 
abnormalities, proteinuria, and polyuria (Uchino et al., 2005, Bonventre and Weinberg, 
2003).  
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Table 1.3. Categories and examples of nephrotoxic drug  
 
(Naughton, 2008, Hoitsma et al., 1991) 
Chemotherapeutic Antiinfectives Antihypertensives Analgesics  Anti HIV Hypoglycemic 
Cisplatin Amikacin Acetazolamide Paracetamol Didanosine  Glibenclamide 
Carboplatin  Amoxicillin Captopril Phenacetin Stavudine  Thiazolidinediones 
Oxaliplatin Amphotericin B Furosemide Acetaminophen Zalcitabine  
Mithramycin Benzylpenicillin Hydralazine Aspiri   
Zoledronate Gentamicin Hydrochlorothiazide Diclofenac   
Ifosfamide Metronidazole Losartan Ketorolac   
Nitrosoureas Gentamicin Mannitol Aceclofenac   
Imatinib Ciprofloxacin Ramipril Piroxicam   
Cyclophosphamide Erythromycin Quinapril Tenoxicam   
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 Treatment for kidney disease   
Dealing with kidney disease is challenging due to lack of a concise definition or etiology. 
Generally, AKI is defined as sudden reduction in the glomerular filtration rate (GFR) in 
response to an ischemia and nephrotoxins, or as a deteriorated GFR for a  period of less 
than 90 days. There is no specific medication or cure for AKI, as it is normally secondary 
to other medical conditions (Ishani et al., 2009). However, several strategies based on the 
underlying causes and extent of illness have been explored in AKI management (NFK, 
2016).  
The first step is to take preventive actions to reduce the chance of AKI in susceptible 
individuals. The second step is identification and elimination of the exact causation. This 
approach, however, is not practical in conditions such as a life-threatening disease that 
urges an immediate medication. In the third step, which is after an episode of AKI, the 
patient should be closely monitored for any alteration in the GFR to prevent reoccurrence 
or progression of AKI (NFK, 2016). 
Despite the efficacy of these strategies in delaying AKI or decreasing its side effects, there 
has been no success in treating this condition. Acute renal diseases are still catastrophic 
conditions with an increasing rate of morbidity and mortality. Therefore, finding new and 
effective treatments for patients affected by the renal disease is highly in demand 
(Chertow et al., 2005). Understanding the mechanisms of kidney dysfunction is of 
fundamental importance in finding new and effective treatments for patients suffering 
from renal disease. For this goal, animal models have proven extremely valuable to 
investigate the pathogenesis of kidney diseases and to evaluate the efficacy of novel 
therapeutic strategies (Dai et al., 2008, Hewitson et al., 2009).  
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 Experimental models for kidney disease 
To understand the pathology and mechanism of renopathy and to test the efficacy of drug 
candidates, many rodent and non-rodent models have been developed. Considering the 
ease of genetic manipulation and accessibility, the non-rodent model is favorable. 
However, the rodent model is still dominant as it mostly covers all the aspects of the 
nephropathy and mimics human physiology. Further, it provides an excellent platform to 
assess nephritis using urinary and hematological parameters and the glomerular filtration 
rate (Dai et al., 2008). 
The best perspective on renal dysfunction has been achievable through medication-
induced kidney failure. A number of popular medications such as cisplatin, gentamicin, 
and fluoxetine have been used to induce nephrotoxicity in animal models (Dai et al., 
2008). Among them, the cisplatin-induced injury model has received special attention 
because of an increasing number of cancer cases and a high incidence of nephrotoxicity 
in cisplatin therapy. One-fifth of drug-induced acute renal failure is due to cisplatin-
therapy, and 30% of the damage caused by cisplatin is irreversible (Arunkumar et al., 
2012). 
Cisplatin is a highly successful antineoplastic drug that has been increasingly administered 
recently due to the rising number of cancer cases and its remarkable efficacy. However, 
the clinical use of cisplatin often limited by life-threatening nephrotoxicity that may result 
in end-stage kidney disease (Leblanc et al., 2016). Cisplatin-induced nephrotoxicity is 
characterized by increased renal vascular damage and decreased GFR. The level of 
damage is measurable by changes in serum/urine clinical chemistry and urine output. In 
the cellular levels, cisplatin mostly targets proximal tubular cells, increases reactive 
oxygen species, and stimulates cell death mechanisms. These make the cisplatin-induced 
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nephrotoxicity an ideal model to study the pathophysiological features of nephrotoxicity 
(Arany and Safirstein, 2003).  
 Chemotherapy 
In the turn of 20th century German scientist Paul Ehrlich, known as the father of 
chemotherapy, described the use of chemical substances in treating diseases as 
chemotherapy (chemo + therapy). In 1907 the first chemotherapy drug “Arsphenamine” 
was derived from arsenic to treat syphilis. The use of mustard gas as chemical warfare in 
World War I, and research on a similar compound known as “nitrogen mustard” during 
World War II, led to the discovery of the first cancer chemotherapy drug (Mustine). Since 
then, the use of cytotoxic, low molecular weight compounds in treating or limiting the 
growth of malignant cells was known as chemotherapy (Miller et al., 2011). Most of the 
chemotherapeutic drugs exert their effect mainly on proliferating cell cycles, as a rapid 
proliferation is the characteristic feature of cancer cells. Alteration of cell cycle phases 
includes interfering with nucleic acid (DNA and RNA) and protein synthesis, 
transcription, and hormonal balance. Chemotherapeutic agents are classified into two 
major groups based on their structure and their effects on different phases of the cell cycle. 
The classes were established as cell cycle-specific agents and cell cycle non-specific 
agents (Barton-Burke et al., 2001) (Table 1.4). The cycle-specific drugs act only during a 
particular cycle of division, whereas non-cycle-specific agents act both during the 
proliferating and resting status. This approach ultimately induces the irreversible death to 
neoplastic cells, and it has been a triumph to halt or diminish the progression of tumors 
(Barton-Burke et al., 2001).  
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Table 1.4. Chemotherapeutic agents  
 
a: First gap or first growth phase; cell prepares for DNA synthesis during this phase.  
b: Synthesis phase; Synthesis of DNA is the major event in this phase.  
c: Second gap or second growth period; synthesis of RNA and proteins continues; production of the mitotic spindle apparatus occurs 
during this phase. 
d: Mitosis phase, a cell divides into two daughter cells in this phase.  
(Barton-Burke et al., 2001) 
Cell cycle phase specific agents 
G1a phase Sb phase G2c phase Md phase 
L-asparaginase 
Prednisone 
Cytarabine 
Gemcitabine 
Hydroxyurea 
Bleomycin 
Etoposide 
Irinotecan 
Docetaxel 
Paclitaxel 
 Vincristine 
Cell cycle phase  non-specific 
Alkylating agents Antibiotics Nitrosoureas      Miscellaneous 
Cyclophosphamide  
Cisplatin 
Carboplatin 
Dactinomycin 
Doxorubicin 
Epirubicin 
Carmustine  
Lomustine 
Semustine 
     Dacarbazine 
     Procarbazine 
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 Chemotherapy side effects  
Chemotherapy is the use of chemical or natural agents to stop the proliferation and 
metastasis of cancer cells. Most of the drugs in this class exert their antitumor activity by 
suppression of cancer cells propagation with no specific drug targets. The non-targeted 
chemotherapeutic agent indiscriminately interacts with cancer and healthy cells with rapid 
division rates. In this circumstance, the drug induces immediate or late sides effect (Table 
1.5). The immediate or common side effects of all chemotherapeutic agents are nausea, 
vomiting, fatigue, alopecia, anemia, and leukopenia. However, the most explicit 
drawbacks are often late or organ-specific side effects. These include neurotoxicity, 
cardiotoxicity, nephrotoxicity, hepatotoxicity, pulmonary toxicity, and ototoxicity 
(Sayed-Ahmed, 2010). Organ-specific toxicity is a limiting step in the treatment of cancer, 
as the administration of an adequate dose is hampered by increased side effects (Chabner 
and Longo, 2011). 
Table 1.5. Side effects of chemotherapy  
(Skeel and Khleif, 2011) 
Immediate (common)  Late (Organ-specific) 
Alopecia 
Anemia 
Gastrointestinal 
Immunosuppression 
Infertility 
Leucopenia 
Myelosuppression 
Nausea and vomiting 
Neurotoxicity 
Ototoxicity (hearing loss) 
Thrombocytopenia  
Cardiotoxicity 
: 
Cyclophosphamide 
Doxorubicin 
Hepatotoxicity 
: Vincristine 
Nephrotoxicity 
: 
Ifosfamide 
Cisplatin 
Neurotoxicity 
: 
Axonal 
Vinca 
Pulmonary 
toxicity 
: Bleomycin 
Cardiotoxicity 
: 
Cyclophosphamide 
Doxorubicin 
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 Cisplatin  
Cisplatin or cis-diamminedichloroplatinum (II) is a structural isomer of Pt (IV) complex, 
which in 1845 synthesized by Michele Peyrone and named as Peyrone's salt. In 1965, it 
was found to inhibit binary fission in Escherichia coli (E. coli) via blocking cell division 
but not growth (Rosenberg et al., 1965). 
Cisplatin was approved by the Food and Drug Administration (FDA) in 1978 as an 
alkylating antineoplastic agent and cytotoxic drug based on platinum for solid tumors. 
Since then, cisplatin became one of the most successful chemotherapy agents ever. It is 
clinically proven to combat different types of cancer including soft tissue, bone, muscle, 
cervical, head and neck, esophageal, and colon cancer (Schrauzer, 2013). Despite the 
remarkable victory, significant challenges remain about the use of cisplatin. The drug 
resistance and its considerable side effects such as ototoxicity, neurotoxicity, and severe 
dose-dependent nephrotoxicity are the major stumbling blocks (Yao et al., 2007). 
 Mechanism of action of cisplatin  
The neutral and inorganic cisplatin initially enters the cell via passive diffusion then by 
active transport to react with biomolecules and exerts its therapeutic effect. For the 
reaction to occur, cisplatin undergoes series of hydrolytic process and form monohydrated 
complexes by sequential replacement of cis-chloro ligands with water molecules (Figure 
1.2). The highly reactive monoaquated binds to DNA, forms DNA-DNA and inter- and 
intrastrand DNA-protein cross links. The formed adducts interfere with normal DNA 
replication and transcription in rapidly dividing cells and arrest the cells’ proliferation. 
Intact DNA lesion leads to irreversible injury and ultimately cell death. This is the most 
probable mechanism of action that has been elucidated for cisplatin-induced cell death. 
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Besides adduct formation, cisplatin binds to phospholipids and phosphatidylserine at the 
cell membrane level. In the cytoplasm, it interacts with cellular constituents and 
nucleophilic sites such as cytoskeletal microfilaments, thiol-containing proteins, peptides, 
and RNA (Figure 1.3) (Jordan and Carmo-Fonseca, 2000). Some studies reported that less 
than 1% of the cisplatin molecules that enter the cell binds to nuclear DNA so that most 
of them end up binding to proteins and other biomolecules. Binding to non-DNA targets 
may contribute to the mechanism of cytotoxicity of cisplatin in cancer cells as well (Yao 
et al., 2007). Even though the mechanism of action of cisplatin is still not clear after 30 
years of clinical use, it is still an effective chemotherapeutic drug that changed the course 
of treatment in cancer therapy to the extent that some of deadliest malignant tumors are 
now curable (Yao et al., 2007). Unfortunately, the profound activity of cisplatin is 
undermined by irreversible toxicity in kidney tissues. This necessitates the development 
of protective agents against cisplatin-induced toxicity (Arany and Safirstein, 2003). 
 
 
Figure 1.2. Mechanism of cisplatin activation. After entering cells, cisplatin loses chloride 
ligands to form aquated species.  
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Figure 1.3. Schematic diagram of major pathways in cisplatin-induced acute tubular cell 
injury. CTR1-membrane copper transporter-1; ERK-extracellular regulated kinase; 
hOCT2- human organic cation transporter 2; RNS- reactive nitrogen species; ROS- 
reactive oxygen species; TNF- α tumor necrosis factor-alpha; TNFR2- tumor necrosis 
factor receptor 2. 
 Cisplatin-induced nephrotoxicity 
Kidneys are the major excretory organs for cisplatin, and are highly vulnerable to its 
cytotoxic effect. Due to high blood flow in the kidneys, low molecular weight, and 
uncharged character of cisplatin, up to 80% of non-active cisplatin passes through 
glomerulus in 24 hours. Renal tissue uptakes and accumulates the cisplatin in the proximal 
tubular epithelial cells up to five times of its serum concentration. The excessive 
accumulation of cisplatin in the renal cortex causes nephrotoxicity (Oh et al., 2014). The 
cisplatin-induced nephropathy is characterized by renal tubular cell injury. The deposited 
cisplatin is metabolized in the proximal tubule epithelial cells. Once the reactive cisplatin 
is formed, it renders the toxic effect through multiple mechanisms. The mechanisms are 
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described as oxidative stress, inflammation, apoptosis, and vascular injury (Figure 1.4) 
(Pabla and Dong, 2008). 
 
 
Figure 1.4. Overview of the pathophysiological events in cisplatin nephrotoxicity (Pabla 
and Dong, 2008). 
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 Cisplatin-induced nephrotoxicity: Oxidative stress 
Cisplatin induces oxidative stress by the production of reactive oxygen species (ROS) and 
attenuation of antioxidant defense capacity. Monoaquated cisplatin inactivates the 
antioxidant enzyme, which leads to depletion of the antioxidant defense system and 
increased oxidative stress. Cisplatin also produces ROS by disruption of mitochondrial 
function. The excess of ROS directly act on cell constituents such as lipids, proteins, RNA 
and DNA, destroy their structure and modulate cell survival (Pabla and Dong, 2008).  
 Cisplatin-induced nephrotoxicity: Inflammation   
Cisplatin renal injury is related to robust inflammatory responses that contribute to renal 
tissue and vascular damage. The cascade of inflammatory responses starts with the 
stimulation of pro-inflammatory cytokines and chemokines in the presence of cisplatin. 
Tumor necrosis factor alpha (TNF-α), as a major cytokine, has a central role in mediating 
the renal injury. TNF-α interferes with the cell death process through the production of 
ROS, and activation of a myriad of apoptotic responses in the kidney. Moreover, it 
increases the expression of inducible nitric oxide synthesis and enhances the production 
of nitric oxide, which leads to cell damage. The level of contribution of each pathway to 
renal injury, however, is not yet defined (Pabla and Dong, 2008). 
 Cisplatin-induced nephrotoxicity: Apoptosis  
Apoptosis is the programmed mode of cell death that is an integral part of normal a cell’s 
death and is characterized by morphological and energetic changes. Sporadic apoptosis, 
however, underlies many medical conditions such as degenerative diseases and ischemic 
damage (Elmore, 2007). Cisplatin initiates apoptosis via intrinsic as well as extrinsic 
pathways. Intrinsic processes start by DNA damage, compromised mitochondrial and 
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endoplasmic reticulum function, and finally cell death. In the extrinsic pathway, 
engagement of death receptors such as TNF-α results in cisplatin-induced renal cell death 
(Arany and Safirstein, 2003). Morphologically, apoptosis starts with renal cell shrinkage, 
chromatin condensation, and membrane blebbing and eventually cells turn into dark oval 
bodies (Elmore, 2007). 
 Cisplatin-induced nephrotoxicity: Vascular injuries   
Kidneys are highly vascular organs with the unique spatial arrangements. The proper 
assembly of kidney vessels with their nephrons is a crucial event leading to the formation 
of a functioning and healthy kidney. The integrity of the vascular endothelium is critical 
for the health of kidney and is determined by the balance of physiological endothelial cell 
turnover. After an inflammatory injury, damaged cells are replaced through induced 
proliferation of surrounding endothelial cells. In disease conditions, constant injury and 
inefficient delivery of angiogenesis factors accelerate vascular injury. A decrease in 
proangiogenic factors are directly related to endothelial cell proliferation and reverse the 
degree of glomerular capillary loss. Loss of functioning vascular systems and disruption 
of blood supply and limited oxygen availability in kidney induces acute hypoxia, and 
eventually ischemic renal failure (Sequeira Lopez and Gomez, 2011). 
Cisplatin is directly toxic to endothelial cells through inflammation and necrosis, as well 
as dysfunction and impairment of vascular autoregulation. Cisplatin induces 
vasoconstriction and develops a hypoxic injury, decreases effective renal plasma flow, 
and finally reduces GFR. In this circumstance, it has been demonstrated that delivery of 
angiogenesis factors and the stimulation of the angiogenesis response can be therapeutic 
to promote glomerular endothelial repair (Goligorsky, 2015). 
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 Pathophysiologic hallmarks of cisplatin-induced nephrotoxicity  
Cisplatin-induced nephrotoxicity is dose-related and cumulative in both animals and 
humans. A dosage of more than 50 mg/m2 can cause renal injury initiated by an acute, 
mainly proximal tubular impairment and preceded by alterations in renal hemodynamics. 
At 48 to 72 hours after cisplatin administration, a depressed renal function is observed due 
to impairment of proximal and distal tubular reabsorptive capacities. The damage is 
symptomized by polyurea, azotemia, and fall in serum sodium, potassium, magnesium, 
phosphorous, and occasionally calcium (Arany and Safirstein, 2003).  
 Current strategies to treat cisplatin-induced nephrotoxicity   
The broad clinical applications of cisplatin not only rely on the therapeutic effect, but also 
on controlled and minimized nephrotoxicity. There are numbers of pathological 
conditions that lead to cisplatin-induced nephropathy. Therefore, the protective strategies 
are classified accordingly to ameliorate or eliminate cisplatin-induced nephrotoxicity. The 
approaches are summarized in Table 1.6 (Pabla and Dong, 2008). 
Clinical efficacy of these nephroprotective strategies is under debate, as most of them have 
been tested only in cultured cell and animal models. Further, many of the same 
pathological conditions are responsible for the cytotoxic activity of cisplatin in malignant 
cells. Regardless of which strategies have been the method of choice, whether it is 
antiinflammation, antioxidant, or antiapoptosis, it reduces cisplatin cytotoxicity. 
Attenuation of cisplatin’s chemotherapeutic activity, restricted the clinical applications of 
current strategies. Therefore, any proposed strategy must be carefully studied to ensure 
that the chemotherapeutic efficacy of cisplatin is not vitiated (Pabla and Dong, 2008). 
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Table 1.6. Experimental strategies to prevent cisplatin-induced nephrotoxicity 
Strategies 
Reduction of renal cisplatin accumulation  
OCT2a inhibitors, e.g., cimetidine or metformin  
Ctr1b inhibitors, e.g., copper Micellar/liposomal cisplatin  
Antioxidant  
Selenium  
Vitamin E catalase  
Superoxide dismutase  
N-acetyl cysteine 
Antiapoptosis  
Caspase inhibitors  
p53c inhibitors 
Antiinflammatory 
TNF-alphad antagonists  
Salicylates 
a: Organic cation transporter 2, b: High affinity copper uptake protein 1 
c: Cellular tumor antigen p53, d: Tumor necrosis factor alpha 
(Miller et al., 2010). 
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 Herbal medicine in treating cisplatin-induced nephrotoxicity  
Despite the lack of consistent information to conclude the efficacy of the herbal products 
in treating chemotherapy side effects, some data show adjunctive administration of plants 
is receiving notable attention recently due to the increase in the life span and quality of 
life of patients (Metri et al., 2013). The data further showed that over 80% of patients have 
been using complementary and alternative approaches adjuvant to chemotherapy. There 
is an agreement within a number of published work that shows that complementary 
formulas from different traditional systems of medicine with various levels of efficacy is 
gaining popularity in reducing side effects of chemotherapy (Cassileth and Deng, 2004). 
Ayurveda is a system of traditional medicine in the Vedic culture of India, and dates back 
to 5000 B.C. Some studies have shown that concurrent administration of Ayurvedic herbal 
formulas with chemotherapy increases the lifetime of patients, compared with those who 
received chemotherapy alone (Metri et al., 2013). Chinese herbal formulas have been used 
widely to neutralize the side effects of cancer treatment. Clinical research has proven that 
Fu Zhen, a combination of Chinese herbal medicines, increased the life span of certain 
cancer patients up to five years (Efferth et al., 2007). PHY906 is a traditional Chinese 
medicine formulation consists of Scutellaria baicalensis Georgi, Glycyrrhiza uralensis 
Fisch., Paeonia lactiflora Pall., and the fruit of Ziziphus jujubeMill. Co-administration of 
PHY906 with current anticancer drug provides a survival benefit. Clinical data showed, 
patients had stable condition after two treatment cycles. Furthermore, Asian patients had 
a higher median overall survival (16.5 months) than non-Asian patients (6.2 months) (Yen 
et al., 2009).  
Herbal intervention is not limited to traditional practice. Many herbal preparations have 
been tested for their efficacy to ameliorate cisplatin-induced nephrotoxicity in preclinical 
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setting (Table 1.7). Previous research suggested that methanolic extract of Angelica 
sinensis protected human kidney cells from the cytotoxic effect of cisplatin (Bunel et al., 
2015b). Another study revealed that silymarin, a natural flavonoid extracted from Silybum 
marianum (milk thistle) seeds, demonstrated a protective effect against cisplatin-induced 
alteration in glomerular and proximal tubular function as well as proximal tubular 
morphology change (Bokemeyer et al., 1996). The effect was further confirmed by one 
study that shows pretreatment with methanolic extract of milk thistle seeds helped to 
reduce cisplatin-induced kidney damage by reducing blood urea nitrogen and serum 
creatinine (Karimi et al., 2005) and produced a significant antioxidant effect (Abouzeinab, 
2015). Post treatment with thymoquinone, a phytochemical from Nigella sativa 
significantly ameliorate elevation in biochemical and physiological parameters as well as 
histopathological changes induced by cisplatin administration (Ali et al., 2015). It also 
protects kidney against doxorubicin (Elsherbiny and El-Sherbiny, 2014), acetaminophen-
induced damage (Aycan et al., 2015). The concurrent administration of thymoquinone 
with omega-3 increased kidney tissue content and antioxidant enzymes in 
ischemia/reperfusion model (Fayez et al., 2014). Water preparation of Nigella sativa 
protects kidney against paracetamol induced oxidative stress (Hamza and Al-Harbi, 2015). 
Chrysanthemum indicum is traditional herbal remedies for inflammatory conditions, 
ethanolic preparation of leaves protect kidney via increasing antioxidant activity and 
porcine kidney cell (LLC-PK1) viability both in in- vivo /-vitro (Kim et al., 2015).  
The use of herbal remedies to ameliorate immediate and late side effects of cisplatin 
therapy has some basis in scientific research. However, the concomitant administration of 
some plants with chemotherapy may cause potential herb-drug interaction. Simultaneous 
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administration of herbs with chemotherapy should be closely monitored as it may render 
the chemotherapeutic agent to be ineffective (Cassileth and Lucarelli, 2003). 
Table 1.7. List of herbal preparation with nephroprotective activity against cisplatin-
induced toxicity.  
Test sample  Activity  Reference 
Azadirachta indica Antioxidant (Abdel Moneim 
et al., 2014) 
Angelica sinensis /Ferulic 
acid  
Increasing renal cell proliferation 
and motility 
Inhibition of β-catenin pathway 
(Bunel et al., 
2015a) 
Curcuma longa Increasing renal cell proliferation  (Kuhad et al., 
2007) 
Glycine max antioxidant and antiinflammatory  (Ekor et al., 
2010) 
Momordica cochinchinensis Antiapoptotic (Jung et al., 
2016) 
Phyllanthus maderaspatensis Antioxidant 
Genotoxicity 
(Chandrasekar 
et al., 2006) 
Paeonia suffruticosa Increasing renal cell proliferation (Sohn et al., 
2009) 
Scutellaria barbata Increasing renal cell proliferation (Sohn et al., 
2009) 
Schisandra sphenanthera  Antioxidant (Jin et al., 2015) 
Scutellaria barbata Antiinflammatory (Lee et al., 2010) 
Sinapis alba Increase cell proliferation (Sohn et al., 
2009) 
Silymarin  Antiapoptotic (Kabel et al., 
2013) 
Silibinin Proximal tubular morphology 
protection 
(Behling et al., 
2006) 
Tinospora cordifolia Antioxidant (Uppuluri et al., 
2013) 
Trichosanthes kirilowii Antioxidant, Antiinfalmmatory  
Increasing renal cell proliferation 
Increased cell viability 
(Seo et al., 2015) 
Ribes diacanthum  Antioxidant (Tilyek et al., 
2016) 
 
 23 
 
 Description of Clinacanthus nutans 
Clinacanthus nutans is an annual plant indigenous mainly to South China, Indonesia, 
Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. Clinacanthus 
nutans grows as an erect herb or rambling shrub. The stem is green and cylindrical, and it 
turns yellow after the plant is dried. Sulcate, bifarious, and pubescent petioles of 0.3–2.0 
cm in length connect leaves to the stem. The leaf blade is green, lancelot, and linear, and 
can grow up to 12 mm long and 4–6 mm wide (Figure 1.5) (GlobinMed, 2015).  
 Taxonomy 
Kingdom  :  Plantae  
Order : Lamiales Bromhead 
Family  :  Acanthaceae  
Genus  :  Clinacanthus  
Species  :  Clinacanthus nutans 
Scientific name   Clinacanthus nutans 
English name :  Sabah snake grass 
Common name    
Indonesia  :  Kitajan (Sunda); Dandang Gendis (Java); Gendis (Central Java) 
Malaysia  :  Belalai Gajah 
South China  :  E zui hua , and niu xu hua 
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Figure 1.5. Clinacanthus nutans; whole plant (https://florafaunaweb.nparks.gov.sg). 
 Traditional uses 
Despite the accessibility of modern medicine, Clinacanthus nutans has been and still is 
being used as a healing herb in South China and South East Asia (GlobinMed, 2015). In 
some cases, it is the first step in health care; in others, it provides a real alternative to 
primary health care approaches in treating conditions such as kidney dysfunction, 
gastrointestinal diseases, inflammation, viral infection lesions, and snake or scorpion 
venom (Siew et al., 2014, Gao et al., 2014). Clinacanthus nutans was also used to promote 
urination, discharge kidney stones, and promote blood circulation that invigorates the 
kidneys.  
